

London, 31 October 2007 Doc. Ref. EMEA/HMPC/234113/2006

This-document-was-valid-from-October-2007-until-November-2013. It-is-now-superseded-by-a-new-version-adopted-by-the-HMPC-on-12-November-2013-and-published-on-the-EMA-website.¶

FINAL

COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA

DISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	October 2006 March 2007 May 2007
ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION	8 May 2007
END OF CONSULTATION (DEADLINE FOR COMMENTS)	15 August 2007
REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	October 2007
ADOPTION BY HMPC	31 October 2007

KEYWORDS	Herbal medicinal products; HMPC; Community herbal monographs; traditional use; <i>Thymus vulgaris</i> L.; <i>Thymus zygis</i> L.; Thymi herba;
	thyme herb.

COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA

1. NAME OF THE MEDICINAL PRODUCT

To be specified for the individual finished product.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION^{1, 2}

Well-established use	<u>Traditional use</u>
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Thymus vulgaris L. or Thymus zygis L. or a mixture of both species, herba (thyme herb)
	 i) Herbal substance Whole leaves and flowers separated from the previously dried stems. ii) Herbal preparations A) Liquid extract (1:1), extraction solvent ethanol 24% (v/v) B) Liquid extract (1:1.16), extraction solvent glycerol 85% (m/m): ethanol 25% (m/m) (0.1:2) C) Liquid extract (1:2-2.5), extraction solvent ammonia solution 10% (m/m): glycerol 85% (m/m): ethanol 90% (v/v): water (1:20:70:109)
	D) Tincture (1:5 or 1:10), extraction solvent ethanol 70% (v/v) E) Soft extract (5-8:1), extraction solvent
	ethanol 25% (v/v) or methanol 25% F) Liquid extract from fresh herb (1:1.5-2.5), extraction solvent water
	G) Dry extract (6-10:1), extraction solvent ethanol 70% (v/v)
	H) Comminuted herbal substance for tea preparation

©EMEA 2007 2/6

 $^{^{1}\,}$ The dried material complies with the Ph. Eur. monograph (ref. 01/2005:0865).

The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

3. PHARMACEUTICAL FORM

Well-established use	Traditional use
	Herbal substance or comminuted herbal substance for tea preparation or other herbal preparations in liquid or solid dosage forms for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Well-established use	<u>Traditional use</u>
	Traditional herbal medicinal product used as an expectorant in cough associated with cold.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2 Posology and method of administration

VV-11 (-1.1'-1 - 1	T1V:1
Well-established use	<u>Traditional use</u>
	Posology Adolescents over 12 years of age, adults and elderly
	Single dose Herbal substance: 1 - 2 g A) Liquid extract: 1 - 2 ml B) Liquid extract: 1.2 - 2.4 ml C) Liquid extract: 1.0 - 4 g
	D) Tincture: 40 drops E) Soft extract: 50 mg F) Liquid extract from fresh herb: 10 ml G) Dry extract: 75 - 200 mg H) Comminuted herbal substance for tea preparation: 1 - 2 g
	Daily dose Herbal substance: 3 - 8 g A) Liquid extract: 3 - 8 ml B) Liquid extract: 3.5 - 9.3 ml C) Liquid extract: 1 - 14 g D) Tincture: 120 drops E) Soft extract: 300 mg
	F) Liquid extract from fresh herb: 30 - 40 ml G) Dry extract: 225 - 600 mg

©EMEA 2007 3/6

H) Comminuted herbal substance for tea preparation: 3 - 8 g

Children between 4 and 12 years of age

C) Liquid extract:

Single dose: 0.5 - 0.9 ml

Daily dose: 2.5 - 4 ml, divided into 3-5 single

doses.

F) Liquid extract from fresh herb:

Single dose: 7 - 10 ml

Daily dose: 14 - 30 ml, divided into 2 - 3 single

doses

The use in children under 4 years of age is not recommended (see 4.4 Special warnings and precaution for use).

Herbal substance and herbal preparations type A, B, D, E, G and H: The use in children under 12 years of age is not recommended (see 4.4 Special warnings and precaution for use).

Duration of use

If the symptoms persist longer than 1 week, a doctor or a qualified health care practitioner should be consulted.

Method of administration

Oral use.

Tea preparation: 1-2 g of herbal substance or comminuted herbal substance for infusion. As an expectorant 3-4 cups of tea per day.

4.3. Contraindications

Well-established use	<u>Traditional use</u>
	Hypersensitivity to the active substance or to other members of the Lamiaceae family.

4.4. Special warnings and precautions for use

Well-established use	<u>Traditional use</u>
	Herbal preparations C and F: The use in children under 4 years of age is not recommended because medical advice should be
	sought.
	Herbal substance and all other types of herbal preparations:

©EMEA 2007 4/6

The use in children under 12 years of age is not recommended because of lack of data.
When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted.
For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	<u>Traditional use</u>	
	None reported	

4.6. Pregnancy and lactation

Well-established use	<u>Traditional use</u>
	Safety during pregnancy and lactation has not
	been established.
	In the absence of sufficient data, the use during
	pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use		<u>Traditional use</u>
		No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	<u>Traditional use</u>
	Hypersensitivity reactions (including one case of anaphylactic shock and one case of Quincke edema) and stomach disorders have been observed. The frequency is not known.

4.9. Overdose

Well-established use	<u>Traditional use</u>
	No case of overdose has been reported.

©EMEA 2007 5/6

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2 Pharmacokinetic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3 Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Tests on reproductive toxicity, genotoxicity and carcinogenicity with extracts have not been performed.

6. PHARMACEUTICAL PARTICULARS

Well-established use	Traditional use
	Not applicable.

7. DATE OF COMPILATION/LAST REVISION

31 October 2007

©EMEA 2007 6/6